Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its New Drug
Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial.
This NDA provides for the use of DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial for locally
advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone
refractory metastatic prostate cancer
